| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56666880a5e2b7703e98a4f9b2d9daf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32a6dc4fb412c3e729924d6872e03ae2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f4eccd2861cf0715a4c6ce7c516de1ca |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55 |
| filingDate |
1996-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2011fd52e04da15517c6c37929175fd6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_255b37fcda7b8d882cd5dacd9c2b773b |
| publicationDate |
1996-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9624373-A2 |
| titleOfInvention |
Combination of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist |
| abstract |
Combinations of an ACE inhibitor and an aldosterone receptor antagonist are described for use in treatment of circulatory disorders. Of particular interest are therapies using captopril or enalapril co-administered with a low-dose of spironolactone. This co-therapy would be particularly useful to treat or prevent the progression of congestive heart failure while avoiding or reducing aldosterone-antagonist-induced side effects such as hyperkalemia. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0180895-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6133304-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0115673-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004082636-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8951742-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0115673-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2567701-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0021509-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009000843-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7417038-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009000843-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004082636-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0021509-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0027380-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7829596-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6410524-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11199552-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010111599-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004082599-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2564856-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2564854-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2564855-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0027380-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9932150-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0180895-A3 |
| priorityDate |
1995-02-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |